Back

Response rate to sacubitril-valsartan in the community. Is there a clear phenotype?

25 May 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 2 - Chronic Heart Failure – Treatment Pharmacotherapy HFA Premium Access Heart Failure 2019

About the speaker

Photo
Doctor Rebabonye Pharithi

Royal Free London NHS Foundation Trust, London (United Kingdom of Great Britain & Northern Ireland)

55 More presentations in this session

Presentation thumbnail
Small tolerated enalapril doses before ARNI administration predicts adverse events during ARNI up-titration
Doctor A. Ntalianis (Athens, GR)
Abstract
Presentation thumbnail
Prescription of sacubitril/valsartan in a real-world population
Mr J. AGOSTINHO (Lisbon, PT)
Abstract
Presentation thumbnail
Use of sacubitril-valsartan in heart failure with reduced ejection fraction: real world experience
Doctor F. Ferreira (Lisbon, PT)
Abstract
Presentation thumbnail
The dangers of non-heart failure hospitalisation for heart failure patients: frequent medication changes without follow up
Ms E. O'Donoghue (Dublin, IE)
Abstract
Presentation thumbnail
Clinical, echocardiographic and cost improvement after the onset with sacubitril-valsartan in mexican patients with heart failure.
Doctor V. Gomez Leiva (San Salvador, SV)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 2 - Chronic Heart Failure – Treatment

The Event

Event poster

Heart Failure 2019

25 May - 28 May 2019
You may be interested in
thumbnail
Congress Presentation
Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion
thumbnail
Congress Presentation
The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources